Quarterly Activities/Appendix 4C Cash Flow Report

• CLIA waiver milestone payments of US$5.0 million from PHASE Scientific and US$0.5 million from BARDA received
• FY26 total revenue of US$13.2 million, up 6% over the pcp, with FebriDx revenue up 875%
• US$0.7 million milestone payment from BARDA for completing paediatric study milestone
• Operating cash inflow for Q4 was US$2.7 million with higher receipts from customers
• Cash balance of US$15.4 million at 30 June 2026

Lumos Diagnostics Holdings Ltd. reported its Quarterly Activity Statement and Appendix 4C Cash Flow Report for the fourth quarter of FY26. Key highlights include the receipt of US$5.0 million from PHASE Scientific and US$0.5 million from BARDA for CLIA waiver milestone payments. Total FY26 revenue was US$13.2 million, up 6% over the previous year, with FebriDx revenue up 875%. A US$0.7 million milestone payment from BARDA for completing a paediatric study milestone was also received. U.S. commercialization of FebriDx is progressing with over 170 healthcare locations across 24 states actively ordering and using the product. Operating cash inflow for Q4 was US$2.7 million with higher receipts from customers. The cash balance at the end of Q4 FY26 was US$15.4 million.